Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
A plain-language summary of the cited sources below. Informational only — not medical advice.
Dosulepin is an older antidepressant that works by increasing the levels of two brain chemicals — noradrenaline and serotonin — which are involved in mood regulation. It does this by blocking their natural removal from the spaces between nerve cells, allowing these chemicals to remain active for longer. Dosulepin also affects several other receptors in the brain and body, including those involved in sleep, blood pressure, and digestion, which explains why it can cause a range of effects beyond mood improvement.
The medication is approved for treating major depression and for keeping depression from returning once someone has improved. After your family member takes a dose, dosulepin stays in the body for quite some time — the average elimination half-life is 51 hours, meaning it takes just over two days for half of a dose to clear. This long duration means the medication builds up gradually and needs to be stopped slowly if the prescriber decides to change treatment.
Common side effects include drowsiness, dry mouth, constipation, and low blood pressure. Some people also experience extrapyramidal symptoms, which are movement-related effects such as stiffness or tremor. These effects happen because dosulepin interacts with multiple systems in the body, not just the ones involved in mood.
There are serious side effects that need urgent medical attention if they occur. These include agranulocytosis and other forms of bone marrow depression, which affect the body's ability to make blood cells. Seizures, heart attack, and stroke have also been reported. Because dosulepin can lower the threshold for seizures, it's contraindicated in people with epilepsy. It should not be used in the period immediately after a heart attack, as it can cause irregular heart rhythms and conduction problems.
Dosulepin must not be used at the same time as another class of antidepressants called monoamine oxidase inhibitors, or within 14 days of stopping one, because the combination can cause dangerous overheating and altered consciousness. It's also contraindicated in people with liver failure or a known allergy to the medication.
“The tricyclics increase the availability of noradrenaline and 5-hydroxytryptamine at central noradrenergic synapses by inhibiting their uptake from nerve endings.”
“The elimination half-life is biphasic; the first phase is 15 to 18 hours. Mean whole body elimination half-life is 51 hours.”
A plain-language summary of the cited sources below. Informational only — not medical advice.
Dosulepin is a non-selective monoamine reuptake inhibitor indicated for the treatment and maintenance treatment of major depression. It inhibits reuptake of both noradrenaline and serotonin at central synapses, while also antagonising histamine H₁, α₁-adrenergic, serotonin 5-HT₂, and muscarinic acetylcholine receptors, and blocking voltage-gated sodium channels. The antidepressant effect is attributed primarily to noradrenaline and possibly serotonin reuptake inhibition.
Elimination is biphasic, with an initial phase of 15 to 18 hours and a mean whole-body elimination half-life of 51 hours. Dosulepin and its active metabolites (dosulepin sulfoxide, northiaden, northiaden sulfoxide) have half-lives ranging from approximately 14 to 46 hours. Common adverse effects include drowsiness, dry mouth, constipation, hypotension, and extrapyramidal symptoms. Serious adverse effects include bone marrow depression (thrombocytopenia, eosinophilia, agranulocytosis), seizures, myocardial infarction, and stroke.
Dosulepin is contraindicated in epilepsy due to seizure-threshold lowering, in the acute recovery phase following myocardial infarction (risk of conduction defects and arrhythmias), in hepatic failure, and in patients with hypersensitivity to the agent. Concomitant use with monoamine oxidase inhibitors, or use within 14 days of MAOI treatment, is contraindicated due to risk of cerebral excitation, coma, and dangerous hyperthermia.
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.